Neurocrine Biosciences (NBIX) Misses Q1 EPS by 114c; misses on guidance

Neurocrine Biosciences (NASDAQ: NBIX) reported Q1 EPS of ($0.51), $1.14 worse than the analyst estimate of $0.63. Revenue for the quarter came in at $410 million versus the consensus estimate of $410.82 million.

GUIDANCE:

Neurocrine Biosciences sees FY2023 revenue of $1.67-1.77 billion, versus the consensus of $1.81 billion.

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.

You May Also Be Interested In

• Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance
• Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance
• Accenture tumbles 16% on guidance cut; announces Dragos, runZero, NetRise deals